Day

January 5, 2015

Federal Circuit’s denial of rehearing Bristol-Myers Squibb v. Teva regarding Entecavir exposes potential issues regarding the utility of later found unexpected results for overcoming obviousness

In the earlier panel opinion, Entecavir was found obvious under the lead compound analysis over a structurally close compound 2’-CDG, which compound at the time...

Categories

Archive

MWZB Newsletter Signup

Subscribe